With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.
https://www.pharmalive.com/wp-content/uploads/2020/07/Novavax-Secures-1.6-Billion-from-U.S.-Government-for-COVID-19-Vaccine-Program-BioSpace-7-7-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-07-07 12:07:032020-07-07 22:29:36Novavax Secures $1.6 Billion for COVID-19 Vaccine Program